Analytical Data
-
Gene name
DPP3
- Application
-
Alternative Names
Dipeptidyl peptidase 3; Dipeptidyl aminopeptidase III; Dipeptidyl arylamidase III; Dipeptidyl peptidase III; DPP III; Enkephalinase B; Dpp3; Mus musculus; Mouse; DPP III; Aminopeptidase; Hydrolase; Metalloprotease; Protease; 3.4.14.4
-
Species
Mouse
-
Source
E. coli
-
Tag
Strep;His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99KK7
-
Expression Region
M1-A738
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Dipeptidyl peptidase III (DPP3) is a membrane-bound enzyme that plays a crucial role in the metabolism of bioactive peptides and is implicated in various physiological processes, including blood pressure regulation and neuropeptide processing. Its involvement in health and disease has attracted significant research interest, particularly in the context of cardiovascular and neurodegenerative disorders. DPP3 is known to exhibit peptidase activity, contributing to the inactivation of a range of peptides such as angiotensin II and substance P, which are key regulators of cardiovascular function and neuronal signaling, respectively. Recent studies have suggested that DPP3 may also be linked to inflammatory responses and cancer progression, highlighting its potential as a therapeutic target. The development of recombinant DPP3 protein allows for in-depth biochemical characterization and facilitates the exploration of its substrate specificity and inhibitor design, which is critical for understanding its role in pathophysiological conditions. Furthermore, generating a stable and active form of DPP3 through recombinant techniques provides a valuable tool for drug discovery and the development of novel therapeutic strategies aimed at modulating its activity for clinical benefits. As research on DPP3 continues to evolve, the recombinant protein holds promise for unraveling the complexities of its biological functions and therapeutic potential.
